白消安个体化给药的群体药代动力学研究现状  

Research development of population pharmacokinetics in clinical individual dosage of busulfan

作　　者：冯新颖 吴云娇 李佳朋 杨长青 赵立波 FENG Xin-ying;WU Yun-jiao;LI Jia-peng;YANG Chang-qing;ZHAO Li-bo(Clinical Research Center,Children's Hospital,Capital University of Medical Sciences,Beijing 100045,China;School of Basic Medicine and Clinical Pharmacy,China Pharmaceutical University,Nanjing 211198,China)

机构地区：[1]首都医科大学附属北京儿童医院临床研究中心,北京100045 [2]中国药科大学基础医学与临床药学学院,南京211198

出　　处：《中国临床药理学杂志》2018年第24期2884-2888,共5页The Chinese Journal of Clinical Pharmacology

基　　金：2017年首都医科大学基础-临床合作课题基金资助项目(17JL08)

摘　　要：白消安是一种细胞周期非特异性的烷化剂,在治疗恶性肿瘤及遗传性疾病的造血干细胞移植前的预处理方案中发挥了重要作用。然而,白消安的治疗窗较窄,且药代动力学(PK)特征的个体间差异较大,易发生血药浓度不足导致的移植失败或浓度过高导致的中毒反应。目前,用群体药代动力学(PPK)方法优化白消安的给药方案已经得到国内外学者的认可。本文通过查阅相关文献,对近年来白消安PPK的研究进展进行综述,以期为国内造血干细胞移植患者建立白消安个体化给药模型、实现精准给药提供参考。Busulfan is a bifunctional alkylating agent which plays a critical role in the preparative regimens prior to hematopoietic stem cell transplantation HSCT) for treatment of malignancies and inherited disorders. However,busulfan has a narrow therapeutic window with high inter-individual variability in pharmacokinetics PK) . There is a high risk of too-low exposure or over-high plasma concentration,associated with engraftment failure and toxicity,respectively. Recently,scholars have reached consensus on the role of population pharmacokinetics PPK) in optimizing busulfan dosage. Our paper reviewed the progress of busulfan PPK studies,aiming to provide a reference to the building of PPK model and busulfan individualized therapy in Chinese population.

关 键 词：白消安 造血干细胞移植 谷胱甘肽转移酶 个体化给药 群体药代动力学 

分 类 号：R979.1[医药卫生—药品]